In Vitro Effects of two Gold Compounds, and D-Penicillamine on the Producn of Interferon Gamma

References

• Browning J. Interferons and rheumatoid arthritis. Insight into interferon therapy. Immunol Tod. 1987; 8: 372
   PubMedGoogle Scholar
• Murray H. W. Interferon - gamma, the activated macrophage, and host defense against microbial challenge. Ann Intern Med. 1988; 108: 595
   PubMed Web of Science ®Google Scholar
• Neighbour P. A., Grayzel A. Interferon production in vitro by leukocytes from patients with systemic lupus erythematosus and rheumatoid arthritis. Clin Exp. Immunol. 1981; 45: 576
   PubMed Web of Science ®Google Scholar
• Ridley M. G., Panayi G. S., Nicholas N. S., Murphy J. Mechanisms of macrophage activation in rheumatoid arthritis. The role of gamma interferon. Clin Exp. Immunol. 1986; 63: 587
   PubMed Web of Science ®Google Scholar
• Malaise M. G., Bastings M., Reuter A. M., et al. In vitro effects of thymopentin on the γ - interferon production by peripheral blood mononuclear cells from normal subjects and from patients with rheumatoid arthritis. Immunol Lett. 1987; 15: 323
   PubMed Web of Science ®Google Scholar
• Seitz M., Napierski I., Augustin R., Hunstein W., Kirchner H. Reduced production of interferon alfa and interferon gamma in leukocyte cultures from patients with active rheumatoid arthritis. Scand J. Rheumatol. 1987; 16: 257
   PubMed Web of Science ®Google Scholar
• Reuter A., Bernier A., Vrindts-Gevaert Y., et al. Production of interferon gamma by peripheral blood mononuclear cells from normal subjects and from patients with rheumatoid arthritis. Clin Exp. Rheumatol. 1988; 6: 347
   PubMed Web of Science ®Google Scholar
• Franchimont P., Reuter A., Vrindts-Gevaert Y., et al. Production of tumour necrosis factor α, Interferon γ and Interleukin-2 by peripheral blood mononuclear cells of subjects suffering from rheumatoid arthritis. Scand J. Rheumatol. 1988; 17: 203
   PubMed Web of Science ®Google Scholar
• Stolzenburg T., Binz H., Forntana A., Felder M., Wagenhauser F. J. Impaired mitogen - induced Interferon γ production in rheumatoid arthritis and related diseases. Scand J. Immunol 1988; 27: 73
   PubMed Web of Science ®Google Scholar
• McKenna R. M., Wilkins J. A., Warrington R. J. Lymphokine production in rheumatoid arthritis and systemic lupus erythematosus. J. Rheumatol. 1988; 15: 1639
   PubMed Web of Science ®Google Scholar
• Lemmel E. M., Franke M., Gaus W., et al. Results of a phase-II clinical trial on treatment of rheumatoid arthritis with recombinant interferon - gamma. Rheumatol. Int. 1987; 7: 127
   PubMed Web of Science ®Google Scholar
• Cesario T. C., Slater L. M., Kaplan H. S., Gupta S., Gorse G. J. Effects of autineoplastic agents on γ-interferon production in human peripheral blood mononuclear cells. Cancer Res. 1984; 44: 4962
   PubMed Web of Science ®Google Scholar
• Ropes M. W., Bennett G. A., Cobb S., Jacox R., Jessar R. A. Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis. 1958; 9: 175
   PubMedGoogle Scholar
• Pinals R. S., Masi A. T., Larsen R. A., et al. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum. 1981; 24: 1308
   PubMed Web of Science ®Google Scholar
• Le J., Lin J-X, Henriksen-De Stefano D., Vilcek J. Bacterial lipopolysaccharide - induced Inteferon-γ production: roles of Interleukin 1 and Interleukin 2. J. Immunol 1986; 136: 4524
   Web of Science ®Google Scholar
• Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest. 1968; 2(Suppl 97)77
   Google Scholar
• Chang T. W., McKinney S., Liu V., Kung P. C., Vilcek J., Le J. Use of monoclonal antibodies as sensitive and specific probes for biologically active human γ - interferon. Proc Nat Acad Sci USA. 1984; 81: 5219
   PubMed Web of Science ®Google Scholar
• Colquhoun D. Lectures on biostatistics. Clarendon Press, Oxford 1971; 143–148; 160–166; 170–213
   Google Scholar
• Russell A. S., Nakashima S., Miller C. In vitro boost of human NK activity by a triethylphosphine gold derivative. Clin Exp. Immunol 1984; 57: 207
   PubMed Web of Science ®Google Scholar
• Oben J. A., Foreman J. C. Stimulatory effects of anti-rheumatic drugs on human neutrophil functions. Immunopharmacol. 1988; 16: 157
   PubMed Web of Science ®Google Scholar
• Froscio M., Murray A. W., Hunt N. P. Enhancement of protein kinase C-mediated EGF receptor phosphorylation by Auranofin. Scand J. Rheumatol. 1988; 17: 281
   PubMed Web of Science ®Google Scholar
• Parente J. E., Walsh M. P., Girard P. R., Kuo J. F., Ng D. S., Wong K. Effects of gold coordination complexes on neutrophil function are mediated via inhibition of protein kinase C. Mol Pharmacol 1989; 35: 26
   PubMed Web of Science ®Google Scholar
• Roitt I. Essential Immunology5th Edn. Blackwell Scientific Publications, Oxford 1984; 260
   Google Scholar
• Luyten F., Suykens S., Veys E., et al. Peripheral blood T lymphocytes subpopulations determined by monoclonal antibodies in active rheumatoid arthritis. J. Rheumatol. 1986; 13: 864
   PubMed Web of Science ®Google Scholar
• Harth M. Auranofin in rheumatoid arthritis. What variables could affect the clinical response. Agents Actions Suppl 1988; 24: 167
   PubMedGoogle Scholar
• Harth M. Modulation of immune responses by gold salts. Agents Actions Suppl 1981; 8: 465
   PubMedGoogle Scholar
• Barrett M. L., Lewis G. P. Unique properties of Auranofin as a potential anti-rheumatic drug. Agents Actions 1986; 19: 109
   PubMedGoogle Scholar
• Johnson H. M. Mechanism of interferon γ production and assessment of immunoregulatory properties. Lymphokines 1985; 11: 33
   Google Scholar
• Wolf E., Hall V. C. Inhibition of in vitro proliferative response of cultured thymocytes to Interleukin-2 by gold sodium thiomalate. Arthritis Rheum 1988; 31: 176
   PubMed Web of Science ®Google Scholar
• Harth M., Cousin K., McCain G. A. Sodium aurothiomalate inhibits T cell responses to Interleukin-2. Immunopharmacol Immunotoxicol. 1988; 10: 141
   PubMed Web of Science ®Google Scholar
• Lipsky P. E, Ziff M. Inhibition of human helper T cell function in vitro by D-Penicillamine and CuSo4. J. Clin Invest. 1980; 65: 1069
   PubMed Web of Science ®Google Scholar
• Gottlieb N. L. Comparative pharmacokinetics of parenteral and oral gold compounds. J. Rheumatol 1982; 9(Suppl 8)99
   Google Scholar
• Rubinstein H. M., Dietz A. A. Serum gold. II. Levels in rheumatoid arthritis. Ann Rheum Dis 1973; 32: 128
   PubMed Web of Science ®Google Scholar
• Butler M., Carruthers G., Harth M., Freeman D., Percy J., Rabenstein D. D-Penicillamine in patients with rheumatoid arthritis. Arthritis Rheum 1982; 25: 111
   PubMed Web of Science ®Google Scholar
• Muijsers A. O., Van De Stadt R. J., Henrichs A. M.A., Ament H. J.W., Van Der Korst J. K. D-Penicillamine in patients with rheumatoid arthritis. Arthritis Rheum 1984; 27: 1362
   PubMed Web of Science ®Google Scholar
• Firestein G. S., Zvaifler N. J. Synovial fluid and synovial tissue interferon suggest that γ - interferon is not the primary microphage activating factor. Arthritis Rheum 1987; 30: 864
   PubMed Web of Science ®Google Scholar
• Buchan G., Barrett K., Fujita T., Taniguchi T., Maini R., Feldmann M. Detection of activated T cell products in the rheumatoid joint using cDNA probes to Interleukin-2 (IL-2) IL-2 receptor and IFNγ. Clin Exp Immunol. 1988; 71: 295
   PubMed Web of Science ®Google Scholar